This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ERN-RND | |
|---|---|
| Name | ERN-RND |
| Type | European Reference Network |
| Established | 2016 |
| Focus | Rare and complex movement disorders and neurodegenerative diseases |
| Region served | European Union |
| Parent organisation | European Commission |
ERN-RND ERN-RND is a European Reference Network for rare neurological diseases focused on rare movement disorders and neurodegenerative diseases. It connects specialist centres, academic hospitals, and patient organisations across the European Union to improve diagnosis, care, and research. ERN-RND fosters cross-border collaboration among clinicians, researchers, and policymakers to harmonise standards and accelerate translational research.
ERN-RND links tertiary centres such as Charité – Universitätsmedizin Berlin, University College London Hospitals NHS Foundation Trust, Klinikum der Universität München, Universitätsspital Zürich, Hospital Clinic Barcelona, and Karolinska University Hospital with expert groups in centres like Azienda Ospedaliero-Universitaria di Bologna, Hôpital de la Pitié-Salpêtrière, Institut Pasteur, St. Olavs Hospital, University of Padua, Sahlgrenska University Hospital, Radboud University Medical Center, CHU de Nantes, Clinique Universitaire Saint-Luc, Hospital Sant Joan de Déu, Rigshospitalet, Academisch Medisch Centrum, CHU Liège, Sheffield Teaching Hospitals NHS Foundation Trust, University Hospital Leuven, Hospital Universitario La Paz, Hannover Medical School, Hospital Universitario Ramón y Cajal, University Hospital of Innsbruck, University Hospital of Greifswald, University Hospital Motol, University Hospital Ljubljana, Vilnius University Hospital Santaros Klinikos, University Clinical Center of Serbia, University Hospital Brno, University Hospital Ostrava, University Hospital Martin, University Hospital Basel, Aarhus University Hospital, University Hospital Galway, Hospital Santa Maria Lisbon, Sant Pau Hospital, Hospital de la Santa Creu i Sant Pau, University of Tartu Hospital, and University Hospital of Nancy to create multidisciplinary networks.
ERN-RND was initiated following policy actions by the European Commission and the establishment of European Reference Networks in 2016, building on prior projects such as Euro-NMD, Solve-RD, RD-Connect, European Brain Council, ERN-RND Grant Consortium, and collaborations with initiatives like Horizon 2020, FP7, IMI, European Research Council, and the Innovative Medicines Initiative. Founding centres included teams associated with Jean-Martin Charcot Hospital, University of Oxford, University of Cambridge, Max Planck Institute for Neurological Research, Institute of Neurology (UCL), MRC Laboratory of Molecular Biology, CNRS, INSERM, CSIC, University of Milan, University of Bologna, Sapienza University of Rome, Università Cattolica del Sacro Cuore, and University of Barcelona. ERN-RND evolved through stakeholder engagement with patient organisations like European Parkinson's Disease Association, Rare Diseases Europe, European Huntington Association, European ALS/MND Association, Eurordis, and societies including European Academy of Neurology, International Parkinson and Movement Disorder Society, Movement Disorder Society, European Federation of Neurological Associations, and World Health Organization regional contacts.
ERN-RND governance connects expert centres and thematic work packages with leadership drawn from institutions such as University of Lübeck, University of Strasbourg, University of Torino, University of Geneva, Trinity College Dublin, University of Edinburgh, University of Freiburg, Medical University of Vienna, Semmelweis University, Jagiellonian University, Masaryk University, Charles University, Nicolaus Copernicus University, and Palacky University Olomouc. The network interacts with regulatory and funding bodies like European Medicines Agency, European Commission Directorate-General for Health and Food Safety, European Centre for Disease Prevention and Control, Council of the European Union, European Parliament, and national health ministries in member states including Germany, France, Italy, Spain, Sweden, Netherlands, Belgium, Portugal, Greece, Poland, Czech Republic, Romania, Hungary, Austria, Denmark, Ireland, Finland, Slovenia, Slovakia, Lithuania, Estonia, Latvia, Croatia, Bulgaria, and Serbia. Advisory input comes from research funders such as Wellcome Trust, Medical Research Council (UK), Italian Ministry of Health, Fonds de la Recherche Scientifique (Belgium), Agence Nationale de la Recherche (France), Deutsche Forschungsgemeinschaft, and philanthropic organisations like European Foundation for the Study of Diabetes, Michael J. Fox Foundation, CHDI Foundation, and Alzheimer's Research UK.
Clinical activities cover diagnosis and management of conditions represented by centres specialising in Parkinson's disease, Huntington's disease, Dystonia, Ataxia, Spinocerebellar ataxia, Multiple system atrophy, Progressive supranuclear palsy, Amyotrophic lateral sclerosis, Cerebrotendinous xanthomatosis, Wilson's disease, Neuroacanthocytosis, Prion disease, Spinobulbar muscular atrophy, and other rare movement disorders through European networks like EURO-NMD and trials coordinated with consortia such as European Huntington's Disease Network, European ALS Consortium, Parkinson's Progression Markers Initiative, EATRIS, ECRIN, COST Actions, BBMRI-ERIC, ELIXIR, EPAD, AMP PD, IMI Big Data for Better Outcomes, and Translational Neuromodeling Unit. ERN-RND facilitates multicentre clinical trials, genotype–phenotype registries linked to platforms such as Orphanet, ClinVar, dbGaP, DECIPHER, EGA (European Genome-phenome Archive), and supports natural history studies from groups including EUROCAT, European Network for Rare and Congenital Anaemias, and disease-specific cohorts like ENROLL-HD. Collaborations extend to pharmaceutical partners including Roche, Novartis, Biogen, Pfizer, Sanofi, Takeda, Merck, Bristol-Myers Squibb, and biotech firms involved in gene therapy and biomarker development.
ERN-RND runs educational programmes with academic partners such as University of Oxford, King's College London, Imperial College London, Karolinska Institutet, Université Paris Cité, Heidelberg University, University of Munich, University of Amsterdam, KU Leuven, Ghent University, University of Warsaw, University of Copenhagen, Leiden University Medical Center, Maastricht University, University of Groningen, University of Utrecht, University of Basel, University of Zurich, University of Helsinki, University of Oslo, and University of Bern. Activities include fellowships, virtual case conferences, webinars, and training aligned with programmes from European Academy of Neurology, European Federation of Neurological Societies, World Federation of Neurology, UEMS (European Union of Medical Specialists), European Board of Neurology, and postgraduate curricula at University of Cambridge and University of Edinburgh.
Patient involvement is central, with partnerships with organisations including Eurordis, European Parkinson's Disease Association, European Huntington Association, European ALS/MND Association, Ataxia UK, Genetic Alliance UK, Dutch Patient Association for Parkinson's, French Association for Research in Movement Disorders, Italian Multiple Sclerosis Society, Spanish Federation of Rare Diseases, Rare Diseases Sweden, and national patient groups across member states. ERN-RND engages with patient representatives at meetings, contributes to patient-reported outcome measure development alongside European Patients' Forum, and works with ethical bodies like European Group on Ethics in Science and New Technologies.
ERN-RND informs policy through links with European Commission, European Parliament, European Medicines Agency, WHO Regional Office for Europe, and national health authorities, contributing evidence to initiatives such as European Pillar of Social Rights, EU4Health, and research frameworks like Horizon Europe. It cooperates with clinical and research networks including European Reference Network for Rare Neurological Diseases (ERN-RND) coordination partners, EATRIS, ECRIN, BBMRI-ERIC, ELIXIR, European Clinical Research Infrastructure Network, and professional societies such as European Academy of Neurology, Movement Disorder Society, International Parkinson and Movement Disorder Society, European Huntington's Disease Network, and European ALS Consortium to influence orphan drug policy, cross-border healthcare directives, and rare disease registries.